Barely Significant
← all excerpts

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.

Alzheimers Res Ther · 2016 · PMC4866415 · PMID 27176461

Europe PMCDOI
1
hedged sentence
0.0850
closest p · 1.7× alpha
0.0850
boldest claim

The sentences

showed a trendp = 0.085so close (0.05 < p ≤ 0.1)
No significant differences were observed in CSF p-tau, although in noncarriers the difference showed a trend ( p = 0.085) favoring the bapineuzumab pooled group (Fig. 3b ). vMRI The vMRI carrier substudy enrolled 540 patients and the noncarrier substudy enrolled 401.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.